Skip to main content
Premium Trial:

Request an Annual Quote

Anne Bailey New Vice President of Diagnostics and Reagents at NaPro Biotherapeutics; James Rosa, Vice President, Strategic Development for CeMines; and Jan Zur Hausen to the Life Sciences Team of Deutsche Venture Capital

NEW YORK, Dec. 26 (GenomeWeb News) -- Anne Bailey has been appointed vice president of diagnostics and reagents at NaPro Biotherapeutics , and general manager of the company's genomics division, the Boulder, Colo., company said Dec. 22.

Bailey indirectly replaces Jeffrey White, who is stepping down Jan. 2 from his post as president of the company's genomics division "to pursue other opportunities." Bailey was most recently vice president of diagnostics at Variagenics , which merged with Hyseq in February to become Nuvelo. Bailey has also held management positions at Avitech Diagnostics, Photest Diagnostics, and Metpath .

NaPro is seeking diagnostic and therapeutic applications for its gene editing technology in cancer and hereditary disease.


James Rosa has joined CeMines of Evergreen, Colo., as vice president, strategic development, the company said Dec. 22. Rosa comes to the company, which is developing its Molecular FingerPrinting technology for the detection and treatment of cancer, from Transat Technologies, where he was director of business development. Prior to that, he was co-initiative manager/business development manager and capability manager/business development manager at Intel . He has also worked at Gambro Renal Products on developing partnerships with other companies and developing products as well as Presearch, Wespace, Goodyear Aerospace, and Raytheon.


Jan zur Hausen has joined the life sciences team of Deutsche Venture Capital, a Munich-based venture capital company, the firm announced Dec. 19. Zur Hausen, who will join the firm in January 2004, was previously managing director of Mulligan BioCapital in Hamburg. Before joining Mulligan in 2000, he worked at MPM Asset Management in South San Francisco, and at MPM Asset Management in Cambridge, Mass. He also held positions at Hoffman-La Roche between 1992 and 1996.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.